Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,364,372.56 in Stock

Key Points

• Alnylam Pharmaceuticals' EVP Pushkal Garg sold 3,022 shares for over $1.36 million, reducing his ownership by 13% to 20,221 shares.
• The company reported a quarterly earnings per share of $0.32, surpassing expectations significantly and showing a 17.3% year-over-year revenue increase.
• Alnylam Pharmaceuticals stock is currently down 1%, trading at approximately $456.35 with a market capitalization of $59.82 billion.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Pushkal Garg sold 3,022 shares of the company's stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the completion of the transaction, the executive vice president owned 20,221 shares of the company's stock, valued at $9,129,377.08. This trade represents a 13.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Pushkal Garg also recently made the following trade(s):

• On Thursday, October 2nd, Pushkal Garg sold 2,937 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $452.05, for a total transaction of $1,327,670.85.
• On Tuesday, August 19th, Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $458.41, for a total transaction of $666,986.55.
• On Monday, August 18th, Pushkal Garg sold 1,396 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $453.27, for a total transaction of $632,764.92.

Alnylam Pharmaceuticals Stock Down 1.0%

Shares of ALNY stock traded down $4.64 on Friday, hitting $456.35. The stock had a trading volume of 969,084 shares, compared to its average volume of 982,632. The firm has a market capitalization of $59.82 billion, a price-to-earnings ratio of -184.76 and a beta of 0.36. The stock's 50 day moving average is $439.02 and its 200-day moving average is $337.29. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business's quarterly revenue was up 17.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company's stock valued at $4,336,064,000 after purchasing an additional 240,534 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock valued at $1,192,988,000 after purchasing an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock valued at $946,466,000 after purchasing an additional 185,783 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company's stock valued at $779,857,000 after purchasing an additional 75,936 shares in the last quarter. Finally, Orbis Allan Gray Ltd boosted its position in shares of Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after purchasing an additional 486,489 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on ALNY. Piper Sandler increased their price objective on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Canaccord Genuity Group increased their price objective on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Oppenheimer raised shares of Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price on the stock in a report on Monday, August 4th. Jefferies Financial Group increased their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a report on Monday, July 7th. Finally, Truist Financial started coverage on shares of Alnylam Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $385.00 target price on the stock. Twenty-four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $439.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.